Watson-Marlow has announced the start of construction on its new state-of-the-art manufacturing facility in the US, with first production due in late 2022.
Following an announcement made earlier this year, the company has provided some further details about the new facility which will be dedicated to its range of products, including peristaltic pumps, tubing, fluid path solutions and BioPure components.
Watson-Marlow specialises in high-quality fluid management solutions for the life sciences and process industries. This significant investment in the expansion of its manufacturing capacity will support the company's future growth in the Americas.
Located in Devens, Massachusetts, US, the 150,000 sqft (14,000 sqm) facility will be close to the life sciences hub in the Cambridge/Boston area.
The site will incorporate a suite of eight ISO14644-1 Class 7 cleanrooms, warehousing and offices, with space for two further cleanrooms within the initial footprint.
With segregated cleanroom and non-cleanroom production capabilities, Watson-Marlow's new facility will strengthen the support the company provides to customers in the region across its core sectors of pharmaceutical and biotechnology, medical diagnostics, and process industries.
"The new US facility is an important milestone in the Watson-Marlow company history and marks a significant commitment to serving our customers in the Americas region," says Andrew Mines, Watson-Marlow Managing Director.
Completion of the facility is due in late 2022, with the first products due to be shipped from the site in late Q4.